NCT03591510 2026-03-13
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
Novartis
Phase 2 Active not recruiting
Clinical Trials
6 trialsNCT03860844 2025-09-09
ISAKIDS
Sanofi
Phase 2 Terminated
NCT00620321 2019-09-09
A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Eli Lilly and Company
Phase 2 Completed
NCT00074737 2014-09-18
Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML
Eleos, Inc.
Phase 2 Completed
NCT00967512 2014-09-18
Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction Course
Eleos, Inc.
Phase 2 Withdrawn
NCT01035502 2013-09-27
A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia
Clavis Pharma
Phase 2 Completed